Novo Nordisk Investor Presentation - First Nine Months of 2016
Novo Nordisk at a glance
Investor presentation
First nine months of 2016
Slide 23
•
Global leader in diabetes care
A focused pharmaceutical company with leading positions
in diabetes, haemophilia and growth hormone
• Significant growth opportunities driven by the diabetes
pandemic and fuelled by global presence and strong R&D
pipeline
• High barriers to entry in biologics
• Operating profit growth targeting 5% on average
• Earnings conversion to cash targeting 90%
Cash generated returned to shareholders
Global insulin market leadership
Global insulin market share: 46%
Europe:
Market share 46%
Pacific:
Market share 47%
USA:
Market share 37%
Region China:
Market share 55%
International Operations:
Market share 55%
changing
diabetes
●Global/regional headquarter ● Manufacturing • R&D facility
Source: IMS MAT August 2016 volume figures
novo nordiskView entire presentation